Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

Kalifa Bojang; Paul Milligan; Margaret Pinder; Tom Doherty; Amanda Leach; Opokua Ofori-Anyinam; Marc Lievens; Kent Kester; Kurt Schaecher; Ripley Ballou; Joe Cohen

doi:10.4161/hv.5.4.7050

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

Kalifa Bojang, Paul Milligan, Margaret Pinder, Tom Doherty, Amanda Leach, Opokua Ofori-Anyinam, Marc Lievens, Kent Kester, Kurt Schaecher, Ripley Ballou, Joe Cohen

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	242-247
Number of pages	6
Journal	Human Vaccines
Volume	5
Issue number	4
DOIs	https://doi.org/10.4161/hv.5.4.7050
Publication status	Published - 2009

Access to Document

10.4161/hv.5.4.7050

Cite this

Bojang, K., Milligan, P., Pinder, M., Doherty, T., Leach, A., Ofori-Anyinam, O., Lievens, M., Kester, K., Schaecher, K., Ballou, R., & Cohen, J. (2009). Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Human Vaccines, 5(4), 242-247. https://doi.org/10.4161/hv.5.4.7050

Bojang, Kalifa ; Milligan, Paul ; Pinder, Margaret ; Doherty, Tom ; Leach, Amanda ; Ofori-Anyinam, Opokua ; Lievens, Marc ; Kester, Kent ; Schaecher, Kurt ; Ballou, Ripley ; Cohen, Joe. / Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. In: Human Vaccines. 2009 ; Vol. 5, No. 4. pp. 242-247.

@article{faa3fc4f0b3b403d8cdfcdd26dc96ce0,

title = "Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia",

author = "Kalifa Bojang and Paul Milligan and Margaret Pinder and Tom Doherty and Amanda Leach and Opokua Ofori-Anyinam and Marc Lievens and Kent Kester and Kurt Schaecher and Ripley Ballou and Joe Cohen",

year = "2009",

doi = "10.4161/hv.5.4.7050",

language = "English",

volume = "5",

pages = "242--247",

journal = "Human Vaccines",

issn = "1554-8600",

publisher = "Taylor & Francis",

number = "4",

}

Bojang, K, Milligan, P, Pinder, M, Doherty, T, Leach, A, Ofori-Anyinam, O, Lievens, M, Kester, K, Schaecher, K, Ballou, R & Cohen, J 2009, 'Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia', Human Vaccines, vol. 5, no. 4, pp. 242-247. https://doi.org/10.4161/hv.5.4.7050

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. / Bojang, Kalifa; Milligan, Paul; Pinder, Margaret; Doherty, Tom; Leach, Amanda; Ofori-Anyinam, Opokua; Lievens, Marc; Kester, Kent; Schaecher, Kurt; Ballou, Ripley; Cohen, Joe.

In: Human Vaccines, Vol. 5, No. 4, 2009, p. 242-247.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

AU - Bojang, Kalifa

AU - Milligan, Paul

AU - Pinder, Margaret

AU - Doherty, Tom

AU - Leach, Amanda

AU - Ofori-Anyinam, Opokua

AU - Lievens, Marc

AU - Kester, Kent

AU - Schaecher, Kurt

AU - Ballou, Ripley

AU - Cohen, Joe

PY - 2009

Y1 - 2009

U2 - 10.4161/hv.5.4.7050

DO - 10.4161/hv.5.4.7050

M3 - Article

VL - 5

SP - 242

EP - 247

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

IS - 4

ER -